347 related articles for article (PubMed ID: 38287834)
1. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Zhao S; Guo Y; Yin X
Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs.
Zhu B; Wei Y; Zhang M; Yang S; Tong R; Li W; Long E
Front Pharmacol; 2023; 14():1286449. PubMed ID: 38027027
[TBL] [Abstract][Full Text] [Related]
3. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
Ni K; Meng L
Clin Res Hepatol Gastroenterol; 2024 May; 48(7):102381. PubMed ID: 38821484
[TBL] [Abstract][Full Text] [Related]
5. Roles of immune dysregulation in MASLD.
Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in age-related metabolic dysfunction-associated steatotic liver disease.
He QJ; Li YF; Zhao LT; Lin CT; Yu CY; Wang D
World J Gastroenterol; 2024 Feb; 30(7):652-662. PubMed ID: 38515956
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions.
Li M; Larsen FT; van den Heuvel MC; Gier K; Gorter AR; Oosterhuis D; Bijzet J; de Meijer VE; Ravnskjaer K; Nagelkerke A; Olinga P
Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474754
[TBL] [Abstract][Full Text] [Related]
8. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
9. Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
Kasprzak-Drozd K; Niziński P; Kasprzak P; Kondracka A; Oniszczuk T; Rusinek A; Oniszczuk A
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612556
[TBL] [Abstract][Full Text] [Related]
10. Updated mechanisms of MASLD pathogenesis.
Li Y; Yang P; Ye J; Xu Q; Wu J; Wang Y
Lipids Health Dis; 2024 Apr; 23(1):117. PubMed ID: 38649999
[TBL] [Abstract][Full Text] [Related]
11. Saturated Fat-Mediated Upregulation of IL-32 and CCL20 in Hepatocytes Contributes to Higher Expression of These Fibrosis-Driving Molecules in MASLD.
Schilcher K; Dayoub R; Kubitza M; Riepl J; Klein K; Buechler C; Melter M; Weiss TS
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686029
[TBL] [Abstract][Full Text] [Related]
12. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
[TBL] [Abstract][Full Text] [Related]
13. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Shin S; Kim J; Lee JY; Kim J; Oh CM
J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
[TBL] [Abstract][Full Text] [Related]
15. Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease.
Li Y; Qi P; Song SY; Wang Y; Wang H; Cao P; Liu Y; Wang Y
Biomed Pharmacother; 2024 May; 174():116585. PubMed ID: 38615611
[TBL] [Abstract][Full Text] [Related]
16. Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis.
Lee JH; Park J; Ahn SB
Nutrients; 2023 Dec; 16(1):. PubMed ID: 38201969
[TBL] [Abstract][Full Text] [Related]
17. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death in alcohol-associated liver disease.
Miyata T; Nagy LE
Clin Mol Hepatol; 2020 Oct; 26(4):618-625. PubMed ID: 32951412
[TBL] [Abstract][Full Text] [Related]
20. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
Li C; Wang T; Song J
Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
